deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04476797

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Galera Therapeutics, Inc.

Conditions NSCLC Non-metastatic SBRT
Interventions GC4711 +SBRT Placebo +SBRT
Updated 17 times since 2020 Last updated: Apr 2, 2024 Started: Oct 18, 2020 Primary completion: Nov 28, 2023 Completion: Nov 28, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis

Other terminated trials from Galera Therapeutics, Inc.

More terminations from Galera Therapeutics, Inc.

Other NSCLC trials with similar outcome

Browse all NSCLC trials

Listed as NCT04476797, this PHASE1/PHASE2 trial focuses on NSCLC and Non-metastatic and remains terminated or withdrawn. Sponsored by Galera Therapeutics, Inc., it has been updated 17 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Jun 2022 · 4 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 20 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jan 2024 — May 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  5. Aug 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Mar 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Aug 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Galera Therapeutics, Inc.
Data source: Galera Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations